Quetiapine XR Shortage: What Providers and Prescribers Need to Know in 2026

Extended-release quetiapine (Seroquel XR, quetiapine XR) is a cornerstone medication for schizophrenia, bipolar spectrum disorders, and adjunctive treatment of major depressive disorder. Supply disruptions — while not reflecting a current active FDA shortage in the US — have recently affected patients in the UK, EU, and Australia, and localized stocking gaps can occur in US pharmacies at any time. This guide is designed to help prescribers proactively manage patients and navigate these situations clinically and administratively.

Overview: Quetiapine XR Pharmacology and Approved Indications

Quetiapine fumarate extended-release (XR) is a dibenzothiazepine atypical antipsychotic that functions primarily as an antagonist at dopamine D2, serotonin 5-HT2A, histamine H1, and alpha-1 adrenergic receptors. The extended-release matrix delivers the drug gradually over approximately 24 hours, allowing for once-daily dosing.

FDA-approved indications for Seroquel XR include:

Schizophrenia (adults; adolescents 13–17)

Acute manic or mixed episodes of bipolar I disorder as monotherapy or adjunct to lithium/divalproex (adults; pediatric 10–17)

Acute depressive episodes of bipolar disorder (adults, monotherapy)

Maintenance of bipolar I disorder as adjunct to lithium or divalproex (adults)

Adjunctive treatment of major depressive disorder (MDD) in adults (XR only; FDA approved 2009)

Current Shortage Landscape: US vs. International

The United States currently has no active FDA-listed shortage of quetiapine or quetiapine extended-release tablets as of early 2026. Multiple generic manufacturers compete in the US market, which generally supports supply stability. However, clinicians should be aware that:

Specific strengths (especially 150 mg XR) may be out of stock at individual pharmacies

Patients in rural or low-density markets may find fewer pharmacies stocking less common strengths

International shortages (UK, EU, Australia in 2024–2025) demonstrate the vulnerability of XR formulations to supply chain disruptions

Clinical Considerations When Switching XR to Immediate-Release

When quetiapine XR is unavailable, the most pharmacologically similar bridge is quetiapine immediate-release (IR). Consider the following when making this switch:

Dosing: Total daily dose is generally equivalent. Switch to the same total mg/day divided BID or TID for IR.

Sedation: IR is associated with higher peak sedation due to faster absorption. Warn patients, particularly for daytime doses.

Adherence: Multiple daily dosing may reduce adherence in some patients; monitor closely.

Food effect: Quetiapine IR can be taken with or without food; XR should be taken without food or with a light meal (~300 calories). Adjust patient counseling accordingly.

Alternative Pharmacotherapies: When XR and IR Are Both Unavailable

If both XR and IR quetiapine are genuinely unavailable, consider the following based on primary indication:

Schizophrenia: Aripiprazole, risperidone, or olanzapine are evidence-based alternatives. Monitor for EPS with risperidone.

Bipolar I mania: Aripiprazole, olanzapine, or risperidone as adjuncts to mood stabilizers (lithium, valproate, lamotrigine).

Bipolar depression: Lurasidone (Latuda) is FDA-approved for bipolar I depression and has a favorable metabolic profile. Cariprazine (Vraylar) is also an option.

MDD augmentation: Aripiprazole (Abilify) and brexpiprazole (Rexulti) are FDA-approved as antidepressant adjuncts.

Boxed Warnings: Critical Safety Reminders

Regardless of which quetiapine formulation or alternative is used, maintain awareness of the class boxed warnings:

Dementia-related psychosis: Not approved for elderly patients with dementia-related psychosis. Analysis of 17 placebo-controlled trials showed a 1.6 to 1.7-fold increase in mortality risk.

Suicidality: Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults when used as antidepressant adjunct; monitor closely, especially at initiation and dose changes.

Supporting Patients in Finding Their Medication

When patients report difficulty filling their Quetiapine XR prescription, consider directing them to medfinder for providers. medfinder calls local pharmacies to check stock availability and texts results to the patient — reducing the burden on both patients and your office staff when medication access issues arise.

For a step-by-step workflow to help your patients access their medication, see: How to Help Your Patients Find Quetiapine XR in Stock: A Provider's Guide